The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Two out of three people under the age of 40 are at risk of prediabetes
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Subscribe To Our Newsletter & Stay Updated
